Innovation
Bioethics
Integrity is built into our values and ESG strategy, as well as our position on conducting clinical trials with the highest respect for patient safety and privacy and in accordance with the highest ethical and legal standards. We are guided in this commitment by a Bioethics Policy Statement, which includes three principles:
- All Bristol Myers Squibb employees understand that they are responsible for compliance with this policy.
- Bristol Myers Squibb is committed to ensuring patient rights and safety are safeguarded at all times.
- Research activities will be performed in compliance with all local regulatory requirements and quality and safety standards in those countries in which we conduct research.
Research safety
BMS follows the principles established by PhRMA, reinforcing our commitment to the safety of research participants, with six core components:
- Protecting research participants.
- Conducting clinical trials.
- Ensuring objectivity in research.
- Providing information about clinical trials.
- Expanded access to investigational drugs.
- Commitment to enhancing diversity in clinical trial participation.
